DGAP-Adhoc

MediClin AG: MEDICLIN publishes forecast for fiscal year 2020 - Seite 2

Since mid-June 2020, all facilities have been gradually returning to normal operation and implementing the higher hygiene and protection regulations. The gradual start of normal operation under the new hygiene requirements is reflected in the increasing occupancy rate in the third quarter and thus in a significantly improved sales and earnings development compared to the two previous quarters.

Group sales were 1.2% below the previous year

In the first nine months of the 2020 financial year, MEDICLIN achieved consolidated sales of EUR 498.7 mill., EUR 6.0 mill. or 1.2% less than in the same period of the previous year. MEDICLIN showed a sales decline of 3.5% at the half-year mark.

The Group operating result was EUR 2.0 million (9 M 2019: EUR 14.9 mill.), the Group EBIT for the first half was EUR -8.8 mill. In addition, the Group EBIT is burdened by a one-off effect of EUR -1.5 mill. from the write-down on the book value in connection with the planned sale of the MediClin Krankenhaus am Crivitzer See GmbH, Crivitz, on December 31, 2020.

Different developments in the segments

In the post-acute segment, sales of EUR 292.7 mill. were EUR 20.6 million or 6.6% below the previous year's figure. The segment EBIT was EUR 0.1 million (9 M 2019: EUR 18.6 million).

Sales in the acute segment increased by EUR 16.4 mill. or 9.3% compared to the first nine months of 2019. The segment EBIT improved compared to the same period of the previous year to EUR 5.5 mill. (9 M 2019: EUR -1.5 mill.).

Investment pace slowed

In the first nine months of the 2020 financial year, EUR 20.5 mill. (gross) were invested (9 M 2019: EUR 34.9 mill.). As a precautionary measure, the investments are below the annual plan for liquidity reasons. As of September 30, 2020, cash and cash equivalents amounted to EUR 88.6 mill. (December 31, 2019: EUR 37.2 mill.). The liquid funds on the reporting date include subsidies for the construction of a new clinic and, as a precaution, reimbursement claims from the Corona protective shield.